Fig. 6

Chromosome 7 abnormalities do not affect the methylation status of the EZH2 promoter. DNA methylation levels were determined by bisulfite pyrosequencing in a cohort of MDS/low blast count AML patients. Four-digit numbers represent DNA patient samples. Continuous color gradients represent methylation values between 0% (grey) and 100% (blue). Mean DNA methylation is indicated for each sample. a DNA hypomethylation of the EZH2 promoter in MDS/AML patients. DNA methylation levels of 11 CpGs located within the EZH2 promoter of 60 patients with (n = 11) or without (n = 49) del(7q)/-7 are shown. Peripheral blood lymphocytes (PBL) from a healthy control and the cell lines KG-1, NB-4, and Raji, as well as 0%, 50%, and 100% in vitro methylated DNA served as controls. b DNA methylation of the p15/INK4B (CDKN2B) promoter of MDS patients. DNA methylation levels of 43 CpGs located within the p15/INK4B promoter of 39 patients with (n = 9) or without (n = 30) del(7q)/-7 are shown. c DNA hypermethylation of the NY-ESO-1 promoter of MDS patients. DNA methylation levels of 15 CpGs located within the NY-ESO-1 promoter of 39 patients with (n = 9) or without (n = 30) del(7q)/-7 are shown. PBL from a healthy control, the human myeloma cell line U226, and CD34 + stem cells served as controls